Tc-99m MIBI to evaluate children with Ewing's sarcoma

Clinical Nuclear Medicine

Volumn 25, Issue 6, 2000, Pages 410-413

  Bar Sever, Zvi ^a,c   Cohen, Ian J ^b,c   Connolly, Leonard P ^d   Horev, Gad ^b,c   Perri, Tamar ^b   Treves, S Ted ^d   Hardoff, Ruth ^a,c  

^a RABIN MEDICAL CENTER   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Ewing's Sarcoma; Multidrug Resistance; P Glycoprotein; Tc 99m MIBI

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADOLESCENT; ADULT; ARTICLE; BONE SCINTISCANNING; CANCER RESISTANCE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EWING SARCOMA; FEMALE; HUMAN; MALE; PROGNOSIS; SCHOOL CHILD;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FEMORAL NEOPLASMS; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; P-GLYCOPROTEIN; PELVIC BONES; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SARCOMA, EWING'S; TECHNETIUM TC 99M SESTAMIBI;

EID: 0034034607     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-200006000-00003     Document Type: Article

References (22)

1. Harms D: New entities, concepts, and questions in childhood tumor pathology. Gen Diagn Pathol 141:1, 1995.
2. Terrier P, Henry-Amar M, Triche TJ, et al: Is neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavorable prognosis? Eur J Cancer 31A:307, 1995.
3. Fletcher B: Response of osteosarcoma and Ewing's sarcoma to chemotherapy: Imaging evaluation. AJR 157:825, 1991.
4. Bacci G, Toni A, Avella M, et al: Long term results in 144 localized Ewing's sarcoma patients treated with combined therapy. Cancer 63:1477, 1989.
5. Picci P, Rougraff BT, Bacci G, et al: Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol 11:1763, 1993.
6. Podoloff DA: The role of radionuclide scans in sarcoma. Hematol Oncol Clin North Am 9:605, 1995.
7. Aktolun C, Bayhan H, Kir M: Clinical experience with Tc-99m MIBI imaging in patients with malignant tumors: Preliminary results and comparison with Tl-201. Clin Nucl Med 17:171, 1992.
8. Caner B, Kitapcl M, Unlu M, et al: Technetium-99m-MIBI uptake in benign and malignant bone lesions: A comparative study with technetium-99m-MDP. J Nucl Med 33:319, 1992.
9. Piwnica-Worms D, Holman BL: Non cardiac applications of hexakis (alkylisonitrile) technetium-99m complexes [Editorial]. J Nucl Med 31:1166, 1990.
10. Piwnica-Worms D, Chiu ML, Budding M, et al: Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53:1, 1993.
11. Kartner N, Riordan JR, Ling V: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285, 1983.
12. Fogel M, Lifschitz-Mercer B, Moll R, et al: Heterogeneity of intermediate filament expression in human testicular seminomas. Differentiation 45:242, 1990.
13. Cattoretti G, Pileri S, Parravicini C, et al: Antigen unmasking on formalin fixed paraffin-embedded tissue sections. J Pathol 171: 83, 1993.
14. Ballinger JR, Hua HA, Berry BW, et al: Tc-99m-sestabmibi as an agent for imaging P-glycoprotein mediated multi-drug resistance: In vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin resistant variant. Nucl Med Commun 16: 253, 1995.
15. Luker GD, Fracasso PM, Dobkin J, et al: Modulation of the multidrug resistance P-glycoprotein: Detection with technetium-99m-sestamibi in vivo. J Nucl Med 38:369, 1997.
16. Kostakoglu L, Guc D, Canpinar H, et al: P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy. J Nucl Med 39:1191, 1998.
17. Kostakoglu L, Elahi N, Kiratli P, et al: Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. J Nucl Med 38:1003, 1997.
18. Andrews DW, Das R, Kim S, et al: Technetium-MIBI as a glioma imaging agent for the assessment of multi-drug resistance. Neurosurgery 40:1323, 1997.
19. Ramanna L, Waxman A, Binney G, et al: Thallium-201 scintigraphy in bone sarcoma: Comparison with gallium-67 and technetium-MDP in the evaluation of chemotherapeutic response. J Nucl Med 31:567, 1990.
20. Menendez LR, Fideler BM, Mirra J: Thallium-201 scanning for the evaluation of osteosarcoma and soft-tissue sarcoma. J Bone Joint Surg 75A:526, 1993.
21. Kostakoglu L, Panicek DM, Divgi CR, et al: Correlation of the findings of thallium-201 chloride scans with those of other imaging modalities and histology following therapy in patients with bone and soft tissue sarcomas. Eur J Nucl Med 22:1232, 1995.
22. Shulkin BL, Mitchell DS, Ungar DR, et al: Neoplasms m a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies. Radiology 194:495, 1995.